[go: up one dir, main page]

DK2018169T3 - Anvendelse af 4,17-beta-dihydroxyandrost-4-en-3-on til behandling af cancer - Google Patents

Anvendelse af 4,17-beta-dihydroxyandrost-4-en-3-on til behandling af cancer

Info

Publication number
DK2018169T3
DK2018169T3 DK07725140.3T DK07725140T DK2018169T3 DK 2018169 T3 DK2018169 T3 DK 2018169T3 DK 07725140 T DK07725140 T DK 07725140T DK 2018169 T3 DK2018169 T3 DK 2018169T3
Authority
DK
Denmark
Prior art keywords
dihydroxyandrost
treatment
beta
cancer
hormone
Prior art date
Application number
DK07725140.3T
Other languages
English (en)
Inventor
Alexander Tobias Teichmann
Original Assignee
Mabel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mabel Gmbh filed Critical Mabel Gmbh
Application granted granted Critical
Publication of DK2018169T3 publication Critical patent/DK2018169T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK07725140.3T 2006-05-12 2007-05-11 Anvendelse af 4,17-beta-dihydroxyandrost-4-en-3-on til behandling af cancer DK2018169T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74712406P 2006-05-12 2006-05-12
EP06009894A EP1854465A1 (en) 2006-05-12 2006-05-12 Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
PCT/EP2007/004220 WO2007131736A2 (en) 2006-05-12 2007-05-11 Use of 4, 17 beta-dihydroxyandrost-4-ene-3-one for treating cancers

Publications (1)

Publication Number Publication Date
DK2018169T3 true DK2018169T3 (da) 2011-02-07

Family

ID=37075285

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07725141.1T DK2018170T3 (da) 2006-05-12 2007-05-11 Lægemiddel mod brystcancer
DK07725140.3T DK2018169T3 (da) 2006-05-12 2007-05-11 Anvendelse af 4,17-beta-dihydroxyandrost-4-en-3-on til behandling af cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07725141.1T DK2018170T3 (da) 2006-05-12 2007-05-11 Lægemiddel mod brystcancer

Country Status (15)

Country Link
US (3) US9138477B2 (da)
EP (3) EP1854465A1 (da)
JP (2) JP5363310B2 (da)
KR (2) KR101403893B1 (da)
CN (2) CN101443016B (da)
AT (1) ATE487483T1 (da)
AU (2) AU2007251822B2 (da)
CA (2) CA2651354C (da)
DE (1) DE602007010447D1 (da)
DK (2) DK2018170T3 (da)
ES (2) ES2391839T3 (da)
PL (2) PL2018170T3 (da)
PT (2) PT2018170E (da)
SI (2) SI2018169T1 (da)
WO (2) WO2007131737A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1854465A1 (en) 2006-05-12 2007-11-14 Alexander Tobias Teichmann Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
EP2060261B1 (en) 2007-11-13 2016-03-09 Athenion AG C-19 steroids for cosmetic uses
EP2949361B1 (en) * 2007-11-13 2017-03-22 Athenion AG C-19 steroids for treating cellulite
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
CA2812438A1 (en) * 2010-10-01 2012-04-05 Indiana University Research And Technology Corporation Treatment of symptoms associated with menopause
TR201816243T4 (tr) 2011-01-31 2018-11-21 Lucolas M D Ltd Aromataz inhibitörlerinin ve antioksidanların kombinasyonları.
WO2015055179A1 (de) * 2013-10-15 2015-04-23 Chelac Holding Gmbh Steroid-carbonsäureester, zusammensetzungen, enthaltend steroid-carbonsäureester und verwendung dieser bei lokal topischer applikation für kosmetische oder dermatologische zwecke
ES2651442T3 (es) * 2014-12-30 2018-01-26 Curadis Gmbh Esteroides C-19 para inhibir la neovascularización
WO2018049042A1 (en) * 2016-09-07 2018-03-15 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating cancers by inhibiting estrogen signaling in myeloid-derived suppressor cells
CN108727453A (zh) * 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用
EP3632445A1 (en) * 2018-10-04 2020-04-08 Curadis GmbH Combinations with a c-19 steroid for treating cancers
RU2679625C1 (ru) * 2018-11-08 2019-02-12 Ильясов Шамиль Сионович ПРИМЕНЕНИЕ 3-О-СУЛЬФАМОИЛОКСИ-6-ОКСА-7β-МЕТИЛ-D-ГОМО-8α-ЭСТРА-1,3,5(10)-ТРИЕН-17а-ОНА ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ВКЛЮЧАЯ ТРИЖДЫ-НЕГАТИВНУЮ ФОРМУ, И СПОСОБ ЕГО ПОЛУЧЕНИЯ
EP3666276A1 (en) * 2018-12-14 2020-06-17 dcic Biopharmaceutical Limited Medication against estrogen-receptor beta (erbeta) positive breast tumor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA639855A (en) 1962-04-17 Societa Farmaceutici Italia 4-halo-3-keto-.delta.4-steroids
BE552152A (da) *
US2744120A (en) 1953-01-14 1956-05-01 Olin Mathieson 1-dehydrotestololactone
US2762818A (en) * 1955-05-26 1956-09-11 Searle & Co 4-hydroxytestosterone and esters thereof
US4235893A (en) 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
US4322416A (en) * 1980-06-27 1982-03-30 Merrell Dow Pharmaceuticals Inc. 10-Alkynyl steroids
US4289762A (en) * 1980-06-27 1981-09-15 Merrell Dow Pharmaceuticals Inc. 10-(1,2-Propadienyl) steroids as irreversible aromatase inhibitors
DE3121153A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
DE3362176D1 (en) 1982-07-14 1986-03-27 Akzo Nv Novel 19-thio-androstane derivatives
GB8721384D0 (en) 1987-09-11 1987-10-21 Erba Farmitalia 17-substituted andro-sta-1 4-dien-3-one derivatives
CA2669753C (en) 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
DE10049736A1 (de) * 2000-09-29 2002-04-18 Jenapharm Gmbh 17alpha-Fluoralkylsteroide, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE10054294A1 (de) * 2000-11-02 2002-05-16 Heinrich Wieland Topische Behandlung bei der Mastalgie
US20030229063A1 (en) * 2002-06-05 2003-12-11 Llewellyn William Charles Use of 4-hydroxytestosterone to lower estrogen levels in humans
US20030049307A1 (en) 2002-08-15 2003-03-13 Gyurik Robert J. Pharmaceutical composition
GB2398495B (en) 2003-01-23 2007-08-22 Kent G Lau A drug delivery preparation comprising at least one anti-tumour drug and a topical carrier for the drug
MXPA06001483A (es) * 2003-08-07 2006-05-15 Schering Corp Inhibidores novedosos de la proteina farnesil transferasa como agentes antitumorales.
AU2004280264A1 (en) * 2003-10-09 2005-04-21 Merck Hdac Research, Llc Thiophene and benzothiophene hydroxamic acid derivatives
EP1692317A4 (en) * 2003-12-12 2007-12-19 Univ Rochester Non-androgen dependent roles for androgen receptor and non-androgen related inhibitors of androgen receptor
JP2008506681A (ja) 2004-07-16 2008-03-06 ファイザー・プロダクツ・インク 抗ｉｇｆ−１ｒ抗体を用いる非血液性の悪性腫瘍の併用療法
EP1854465A1 (en) 2006-05-12 2007-11-14 Alexander Tobias Teichmann Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers

Also Published As

Publication number Publication date
WO2007131736A3 (en) 2008-03-06
ES2355530T3 (es) 2011-03-28
JP2009536931A (ja) 2009-10-22
CN101443017A (zh) 2009-05-27
AU2007251822B2 (en) 2012-08-16
CA2651354C (en) 2015-11-17
CN101443016A (zh) 2009-05-27
PT2018170E (pt) 2012-10-25
CA2652057C (en) 2015-07-07
KR101403893B1 (ko) 2014-06-20
WO2007131736A2 (en) 2007-11-22
SI2018169T1 (sl) 2011-02-28
PL2018170T3 (pl) 2013-01-31
PT2018169E (pt) 2011-01-19
PL2018169T3 (pl) 2011-04-29
WO2007131737A2 (en) 2007-11-22
JP5363310B2 (ja) 2013-12-11
US9138477B2 (en) 2015-09-22
JP2009536932A (ja) 2009-10-22
US20100061975A1 (en) 2010-03-11
CN101443016B (zh) 2012-09-05
EP2018169B1 (en) 2010-11-10
AU2007251823A1 (en) 2007-11-22
DE602007010447D1 (de) 2010-12-23
SI2018170T1 (sl) 2012-12-31
EP2018170B1 (en) 2012-07-25
KR20090009855A (ko) 2009-01-23
AU2007251822A1 (en) 2007-11-22
US9114163B2 (en) 2015-08-25
AU2007251823B2 (en) 2012-09-06
ES2391839T3 (es) 2012-11-30
CA2652057A1 (en) 2007-11-22
US9610292B2 (en) 2017-04-04
ATE487483T1 (de) 2010-11-15
KR101403895B1 (ko) 2014-06-20
US20160030448A1 (en) 2016-02-04
KR20090010189A (ko) 2009-01-29
EP1854465A1 (en) 2007-11-14
CA2651354A1 (en) 2007-11-22
CN101443017B (zh) 2013-07-31
US20090111784A1 (en) 2009-04-30
WO2007131737A3 (en) 2008-05-02
EP2018170A2 (en) 2009-01-28
JP5363309B2 (ja) 2013-12-11
DK2018170T3 (da) 2012-10-22
EP2018169A2 (en) 2009-01-28

Similar Documents

Publication Publication Date Title
DK2018169T3 (da) Anvendelse af 4,17-beta-dihydroxyandrost-4-en-3-on til behandling af cancer
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
TW200612892A (en) Novel compounds
SG163585A1 (en) Melanocortin receptor ligands
ATE469895T1 (de) Cgrp-rezeptorantagonisten
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
PL1853602T3 (pl) Związki chemiczne
SI1853588T1 (sl) Kemične spojine
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
JO2645B1 (en) Vehicles
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
MX2010006388A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina.
CY1113820T1 (el) Παραγωγα 4-αλκοξυπυριδαζινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
TW200738659A (en) Novel compounds
TW200740814A (en) Compounds
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
PT1988914E (pt) Combinação de análogos de somatostatina com diferente selectividade para subtipos do receptor da somatostatina humana
TW200640863A (en) Compounds which potentiate glutamate receptor and uses thereof in medicine
CL2008001261A1 (es) Compuestos derivados de 4-(benzoxanol-2-ilamino), ligandos del receptor npy y5; composiciones farmaceuticas que los contienen; y sus uso en la preparacion de medicamentos utiles en el tratamiento de la depresion, la ansiedad o la obesidad.
GEP20146025B (en) Chromenone derivatives as trpv3 antagonists
UA93197C2 (ru) Производные пиразолиламинопиридина, способ их получения, их применения и фармацевтическая композиция (варианты)